Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Zacks Investment Research on MSN4d
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough StudyShares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER ...
Clinical Trials Arena on MSN4d
Trevi’s Phase IIb chronic cough success spikes stock by 71%The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Trevi Therapeutics (TRVI) announced topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC. Haduvio ...
Trevi Therapeutics (Nasdaq: TRVI) reported promising results from a mid-stage study of its experimental chronic cough ...
The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...
New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...
Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential ...
Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback